Law360, New York (May 08, 2006, 12:00 AM ET) -- Europe’s highest court has issued a ruling making it more difficult for pharmaceutical companies to protect the market for blockbuster drugs, shooting down an appeal that sought five more years of exclusive rights for the brain-tumor treatment Gliadel.
The precedent established by the European Court of Justice sets a new, tougher legal standard for what constitutes active ingredients in a drug, which could cost brand-name drug makers large amounts in lost sales by limiting their ability to seek exclusivity extensions.
The European appeals court inherited the...
E.U. Court Tightens Rules For Protecting Drug Patents
To view the full article, take a free trial now.
